SLDB insider filings
Solid Biosciences Inc. — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2026-10-26. Screen SLDB transaction legs live →
Insider transaction summary — last 90 days
2026-08-23 to 2026-11-21, from the filings listed below: 3 insider filings (Forms 3/4/5). Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 1 leg across 1 filing by 1 insider — 4,374 shares, $24,582 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 5.
- Largest priced transaction: sale of 4,374 shares @ $5.62 ($24,582) by Brooks Gabriel, filed 2026-10-20.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Brooks Gabriel — Chief Medical Officer | 1 | — | 1 leg · 4,374 sh · $24,582 | 2 |
| SMITH IAN F — Director | 1 | — | — | 2 |
| Ganot Ilan — Director | 1 | — | — | 1 |
Recent insider filings — Solid Biosciences Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-10-26 | 4 | Ganot Ilan — Director | Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
| 2026-10-20 | 4 | Brooks Gabriel — Chief Medical Officer | Option exercise (M): 9,750 · Sale (S): 4,374 @ $5.62 · Option exercise (M): 9,750 (derivative) @ $0 | EDGAR |
| 2026-10-06 | 4 | SMITH IAN F — Director | Option exercise (M): 3,440 · Option exercise (M): 3,440 (derivative) @ $0 | EDGAR |
| 2026-07-07 | 4 | SMITH IAN F — Director | Option exercise (M): 3,440 · Option exercise (M): 3,440 (derivative) @ $0 | EDGAR |
| 2026-06-11 | 4 | Ganot Ilan — Director | Grant/award (A): 77,500 (derivative) @ $0 | EDGAR |
| 2026-06-11 | 4 | Keresty Georgia — Director | Grant/award (A): 77,500 (derivative) @ $0 | EDGAR |
| 2026-06-11 | 4 | Kahn Clare — Director | Grant/award (A): 77,500 (derivative) @ $0 | EDGAR |
| 2026-06-11 | 4 | Sullivan Lynne Marie — Director | Grant/award (A): 77,500 (derivative) @ $0 | EDGAR |
| 2026-06-11 | 4 | Stone Adam Leo — Director | Grant/award (A): 77,500 (derivative) @ $0 | EDGAR |
| 2026-06-11 | 4 | Freed Martin I — Director | Grant/award (A): 77,500 (derivative) @ $0 | EDGAR |
| 2026-06-11 | 4 | Nagendran Sukumar — Director | Grant/award (A): 77,500 (derivative) @ $0 | EDGAR |
| 2026-06-11 | 4 | SMITH IAN F — Director | Grant/award (A): 77,500 (derivative) @ $0 | EDGAR |
| 2026-06-11 | 4 | PERCEPTIVE ADVISORS LLC — Director, 10% owner EDELMAN JOSEPH — Director, 10% owner PERCEPTIVE LIFE SCIENCES MASTER FUND LTD — Director, 10% owner | Grant/award (A): 77,500 (derivative) @ $0 | EDGAR |
| 2026-04-21 | 4 | Brooks Gabriel — Chief Medical Officer | Grant/award (A): 58,847 (derivative) @ $0 | EDGAR |
| 2026-04-21 | 4 | Herzich Paul — Chief Technology Officer | Grant/award (A): 54,925 (derivative) @ $0 | EDGAR |
| 2026-04-21 | 4 | Tan Kevin — CFO & Treasurer | Grant/award (A): 56,647 (derivative) @ $0 | EDGAR |
| 2026-04-21 | 4 | Hanrahan Jessie — Chief Regulatory Officer | Grant/award (A): 54,925 (derivative) @ $0 | EDGAR |
| 2026-04-21 | 4 | Cumbo Alexander — President and CEO, Director | Grant/award (A): 169,401 (derivative) @ $0 | EDGAR |
| 2026-04-21 | 4 | Howton David T — Chief Operating Officer | Grant/award (A): 79,341 (derivative) @ $0 | EDGAR |
| 2026-04-02 | 4 | SMITH IAN F — Director | Option exercise (M): 3,441 · Option exercise (M): 3,441 (derivative) @ $0 | EDGAR |
| 2026-03-11 | 4 | PERCEPTIVE ADVISORS LLC — Director, 10% owner EDELMAN JOSEPH — Director, 10% owner PERCEPTIVE LIFE SCIENCES MASTER FUND LTD — Director, 10% owner | Grant/award (A): 8,912,655 (derivative) @ $5.61 | EDGAR |
| 2026-02-18 | 4 | Hanrahan Jessie — Chief Regulatory Officer | Option exercise (M): 8,125 · Sale (S): 4,134 @ $5.82 · Option exercise (M): 8,125 (derivative) @ $0 | EDGAR |
| 2026-02-18 | 4 | Ganot Ilan — Director | Option exercise (M): 4,861 · Sale (S): 2,658 @ $5.82 · Option exercise (M): 4,861 (derivative) @ $0 | EDGAR |
| 2026-02-18 | 4 | Herzich Paul — Chief Technology Officer | Option exercise (M): 7,187 · Sale (S): 3,616 @ $5.82 · Option exercise (M): 7,187 (derivative) @ $0 | EDGAR |
| 2026-02-18 | 4 | Brooks Gabriel — Chief Medical Officer | Option exercise (M): 10,937 · Sale (S): 0 @ $5.82 · Option exercise (M): 10,937 (derivative) @ $0 | EDGAR |
| 2026-02-18 | 4 | Tan Kevin — CFO & Treasurer | Option exercise (M): 10,625 · Sale (S): 5,404 @ $5.82 · Option exercise (M): 10,625 (derivative) @ $0 | EDGAR |
| 2026-02-18 | 4 | Cumbo Alexander — President and CEO, Director | Option exercise (M): 30,031 · Sale (S): 16,644 @ $5.82 · Option exercise (M): 30,031 (derivative) @ $0 | EDGAR |
| 2026-02-18 | 4 | Howton David T — Chief Operating Officer | Option exercise (M): 14,687 · Sale (S): 7,469 @ $5.82 · Option exercise (M): 14,687 (derivative) @ $0 | EDGAR |
| 2026-02-06 | 4 | Ganot Ilan — Director | Sale (S): 7,205 @ $6.44 | EDGAR |
| 2026-02-06 | 4 | Tan Kevin — CFO & Treasurer | Sale (S): 14,783 @ $6.44 | EDGAR |
| 2026-02-06 | 4 | Brooks Gabriel — Chief Medical Officer | Sale (S): 12,616 @ $6.44 | EDGAR |
| 2026-02-06 | 4 | Hanrahan Jessie — Chief Regulatory Officer | Sale (S): 12,348 @ $6.44 | EDGAR |
| 2026-02-06 | 4 | Herzich Paul — Chief Technology Officer | Sale (S): 10,905 @ $6.44 | EDGAR |
| 2026-02-06 | 4 | Cumbo Alexander — President and CEO, Director | Sale (S): 48,913 @ $6.44 | EDGAR |
| 2026-02-06 | 4 | Howton David T — Chief Operating Officer | Sale (S): 18,894 @ $6.44 | EDGAR |
| 2026-02-02 | 4 | Tan Kevin — CFO & Treasurer | Option exercise (M): 56,646 · Option exercise (M): 33,075 · Sale (S): 26,837 @ $6.44 · Option exercise (M): 56,646 (derivative) @ $0 · Grant/award (A): 187,000 (derivative) @ $0 · Grant/award (A): 93,500 (derivative) @ $0 · +1 more | EDGAR |
| 2026-02-02 | 4 | Hanrahan Jessie — Chief Regulatory Officer | Option exercise (M): 54,925 · Option exercise (M): 27,625 · Sale (S): 26,535 @ $6.44 · Option exercise (M): 54,925 (derivative) @ $0 · Grant/award (A): 190,000 (derivative) @ $0 · Grant/award (A): 95,000 (derivative) @ $0 · +1 more | EDGAR |
| 2026-02-02 | 4 | Brooks Gabriel — Chief Medical Officer | Option exercise (M): 58,847 · Option exercise (M): 28,225 · Sale (S): 28,335 @ $6.44 · Option exercise (M): 58,847 (derivative) @ $0 · Grant/award (A): 207,450 (derivative) @ $0 · Grant/award (A): 103,750 (derivative) @ $0 · +1 more | EDGAR |
| 2026-02-02 | 4 | Herzich Paul — Chief Technology Officer | Option exercise (M): 54,925 · Option exercise (M): 24,675 · Sale (S): 26,250 @ $6.44 · Option exercise (M): 54,925 (derivative) @ $0 · Grant/award (A): 170,000 (derivative) @ $0 · Grant/award (A): 85,000 (derivative) @ $0 · +1 more | EDGAR |
| 2026-02-02 | 4 | Ganot Ilan — Director | Option exercise (M): 15,000 · Grant/award (A): 70,900 (derivative) @ $0 · Grant/award (A): 35,450 (derivative) @ $0 · Option exercise (M): 15,000 (derivative) @ $0 | EDGAR |
| 2026-02-02 | 4 | Cumbo Alexander — President and CEO, Director | Option exercise (M): 169,401 · Option exercise (M): 100,400 · Sale (S): 80,258 @ $6.44 · Option exercise (M): 169,401 (derivative) @ $0 · Grant/award (A): 509,850 (derivative) @ $0 · Grant/award (A): 254,900 (derivative) @ $0 · +1 more | EDGAR |
| 2026-02-02 | 4 | Howton David T — Chief Operating Officer | Option exercise (M): 79,341 · Option exercise (M): 42,275 · Sale (S): 37,771 @ $6.44 · Option exercise (M): 79,341 (derivative) @ $0 · Grant/award (A): 210,200 (derivative) @ $0 · Grant/award (A): 105,100 (derivative) @ $0 · +1 more | EDGAR |
| 2026-01-30 | 4 | Ganot Ilan — Director | Option exercise (M): 389 · Sale (S): 191 @ $6.59 · Option exercise (M): 3,884 · Option exercise (M): 389 (derivative) @ $0 · Option exercise (M): 3,884 (derivative) @ $0 | EDGAR |
| 2026-01-13 | 4 | Tan Kevin — CFO & Treasurer | Option exercise (M): 11,250 · Sale (S): 5,704 @ $5.27 · Option exercise (M): 11,250 (derivative) @ $0 | EDGAR |
| 2026-01-07 | 4 | SMITH IAN F — Director | Option exercise (M): 4,573 · Grant/award (A): 18,012 (derivative) @ $0 · Grant/award (A): 13,761 (derivative) @ $0 · Option exercise (M): 4,573 (derivative) @ $0 | EDGAR |
| 2026-01-06 | 4 | Ganot Ilan — Director | Option exercise (M): 2,994 · Sale (S): 1,053 @ $5.43 · Option exercise (M): 2,994 (derivative) @ $0 | EDGAR |
| 2025-12-04 | 4 | Hanrahan Jessie — Chief Regulatory Officer | Option exercise (M): 11,862 · Sale (S): 4,483 @ $5.11 · Option exercise (M): 11,862 (derivative) @ $0 | EDGAR |
| 2025-12-04 | 4 | Herzich Paul — Chief Technology Officer | Option exercise (M): 7,239 · Sale (S): 2,701 @ $5.11 · Option exercise (M): 7,239 (derivative) @ $0 | EDGAR |
| 2025-12-04 | 4 | Cumbo Alexander — President and CEO, Director | Option exercise (M): 28,612 · Sale (S): 10,808 @ $5.11 · Option exercise (M): 28,612 (derivative) @ $0 | EDGAR |
| 2025-12-04 | 4 | Howton David T — Chief Operating Officer | Option exercise (M): 13,051 · Sale (S): 4,932 @ $5.11 · Option exercise (M): 13,051 (derivative) @ $0 | EDGAR |
Recent 8-K events — Solid Biosciences Inc.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-06 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-10 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-04-10 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-03-12 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events | EDGAR |
| 2026-03-06 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.02 — Results of Operations and Financial Condition 3.02 — Unregistered Sales of Equity Securities 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-03 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-06-13 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-05-15 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-02-18 | 8-K | 2.02 — Results of Operations and Financial Condition 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-02-18 | 8-K | 8.01 — Other Events | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=SLDB returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs